What Happens When You Stop Taking Ozempic or Mounjaro?
It's one of the most common questions in every GLP-1 subreddit, doctor's office, and group chat: what happens to the weight when you stop? The short answer: most of it comes back. But there are real strategies that influence the outcome.
What the Clinical Trials Show
Semaglutide: STEP 1 Extension & STEP 4
The STEP 1 extension study followed participants for one year after stopping semaglutide 2.4 mg:
The STEP 4 trial was even more direct. All participants took semaglutide for 20 weeks, then half switched to placebo:
Continued semaglutide
Lost an additional 7.9% body weight
Switched to placebo
Regained 6.9% body weight within 12 weeks
Tirzepatide: SURMOUNT-4
The picture with tirzepatide is similar — and a recent post-hoc analysis adds important detail:
- After 36 weeks of tirzepatide, participants achieved ~20.9% weight loss
- Those switched to placebo regained an average of 14.0% over the next 52 weeks
- A post-hoc analysis (JAMA Internal Medicine, February 2026) found 82% of participants who stopped tirzepatide regained 25% or more of their lost weight within one year
Cardiometabolic improvements (blood pressure, cholesterol, blood sugar) also reversed proportionally to weight regain.
Why Does This Happen?
A systematic review and meta-analysis published in eClinicalMedicine(The Lancet, November 2025) identified the biological mechanisms behind “metabolic rebound”:
Obesity is a chronic condition with biological drivers. Removing the medication doesn't remove the underlying biology — it re-emerges.
The Nuance: It's Not All-or-Nothing
While the average is two-thirds regain, individual variation is enormous. Some people maintain most of their loss. The factors that seem to matter:
Lifestyle changes built during treatment
- People who used the appetite suppression window to establish exercise habits and change their relationship with food tend to retain more
- The drug buys you time to build habits — the habits are what carry you
Length of treatment
- Longer treatment periods may lead to more durable metabolic adaptation
- Emerging evidence suggests staying on treatment for 12+ months creates more lasting changes than shorter courses
Maintenance dosing
- Low-dose maintenance (instead of full stop) is increasingly common in clinical practice
- STEP 4 data proved that continued treatment, even at lower doses, preserves results
The real question isn't “can I stop?” — it's “what's the minimum effective dose?” Most obesity medicine specialists now frame GLP-1s as chronic medications, similar to blood pressure drugs. You wouldn't stop your blood pressure medication because your numbers improved — the numbers improved because of the medication.
Practical Strategies
If you're considering stopping or tapering your GLP-1 medication:
The Bottom Line
The evidence is unambiguous: most people regain a significant portion of lost weight after stopping GLP-1 medications.This doesn't mean the drugs don't work — it means they work while you take them, similar to most chronic disease medications.
The emerging consensus in obesity medicine is that for many patients, some form of ongoing treatment — whether full dose, maintenance dose, or periodic use — is the most realistic path to sustained results.
We'll update this article as new data on tapering protocols and maintenance strategies emerges.
Sources
- Rubino D, et al. “Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance.” JAMA. 2021;325(14):1414–1425.
- Wilding JPH, et al. “Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.” Diabetes Obes Metab. 2022;24(8):1553–1564.
- Aronne LJ, et al. “Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4).” JAMA. 2024;331(1):38–48.
- “Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal: Post Hoc Analysis of SURMOUNT-4.” JAMA Intern Med. 2026.
- “Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis.” eClinicalMedicine (The Lancet). 2025.
Educational content only. This does not constitute medical advice. Always consult a qualified healthcare provider before changing your medication regimen. PeptidePub is an independent publication.